Dapagliflozin Patent - Patent2Profit

Interim Injunction in the Empagliflozin “Jardiance” Patent Dispute

November 6, 2025 by Patent2Profit

Interim Injunction in the Empagliflozin Jardiance Dispute

On Nov 5, 2025, the Patents Court handed down an important interim injunction decision in Dr Reddy’s Laboratories (UK) Ltd v Boehringer Ingelheim International GmbH, neutral citation EWHC 2834 (Pat). Michael Tappin KC, sitting as a Deputy Judge, granted interim relief restraining Dr Reddy’s from dealing in empagliflozin (the active in Jardiance) in the UK … Read more

UK Court of Appeal Revokes Dapagliflozin Patent: Key Lessons on Plausibility and Inventive Step

August 13, 2025August 12, 2025 by Patent2Profit

uk court of appeal revokes dapagliflozin patent plausibility inventive step lessons

UK Court of Appeal Judgment on Dapagliflozin Patent UK Court of Appeal Judgment: Dapagliflozin Patent In a recent landmark judgment, the UK Court of Appeal upheld the High Court’s April 2025 decision invalidating the UK equivalent patent of EP1506211B1 (expired on May 14, 2023) for Dapagliflozin and its associated Supplementary Protection Certificate (SPC) (Expiry Date: … Read more

We would love to hear from you! Get in touch with us for any queries, feedback, or collaboration opportunities.